Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

A Markov decision process for response-adaptive randomization in clinical trials

Robust Blocked Response-Adaptive Randomization Designs

A practical Response Adaptive Block Randomization (RABR) design with analytic type I error protection

Response adaptive randomization procedures in seamless phase II/III clinical trials.

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

Implementing Response-Adaptive Randomisation in Stratified Rare-disease Trials: Design Challenges and Practical Solutions

Group Response-Adaptive Randomization With Delayed and Missing Responses

Adaptive Clinical Trials: Exploiting Sequential Patient Recruitment and Allocation

Comparison of response adaptive randomization features in multiarm clinical trials with control

Adaptive Randomization for Clinical Trials with Delayed Response

Constrained Markov decision processes for response-adaptive procedures in clinical trials with binary outcomes

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints

Implementation of statistical features of a Bayesian two-armed responsive adaptive randomization trial with post hoc analysis of time trend drift

Adaptive Allocation Theory in Clinical Trials

Adaptive Randomization Methods for Sequential Multiple Assignment Randomized Trials (SMARTs) via Thompson Sampling

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Bayesian response adaptive randomization design with a composite endpoint of mortality and morbidity

A response‐adaptive randomization procedure for multi‐armed clinical trials with normally distributed outcomes

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy